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INTRODUCTION
Hypertension is a common comorbidity in diabetes and is a 
major risk factor for atherosclerotic cardiovascular disease and 
end-stage renal disease.1 Studies have shown that the majority 
of diabetics develop hypertension during their lifetime.2,3 In 
the Multiple Risk Factor Intervention Trial (MRFIT) study, a co-
hort of 347978 men aged 35–57 years followed up for an aver-
age of 12 years, the relative risk for cardiovascular death in dia-
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Recently, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) blood pressure (BP) trial enrolled 4733 participants 
with type 2 diabetes and randomized them to a target systolic blood pressure (SBP) of less than 120 mm Hg or 140 mm Hg. De-
spite the significant difference in the achieved SBP, there was no significant difference in the incidence of primary outcomes. 
Based on this evidence, the target SBP for diabetics has been revised in the majority of major guidelines. However, there is a 
steeper association between SBP and stroke in Asians than other ethnicities, with stroke being the leading cause of cardiovascular 
mortality. This suggests that target BP in the Asian region should be tailored towards prevention of stroke. In the ACCORD study, 
the intensive BP treatment was associated with significant reductions in both total stroke and non-fatal stroke. The results from 
the ACCORD study are supported by a subgroup analysis from the ONgoing Telmisartan Alone and in combination with Ramipril 
Global Endpoint Trial (ONTARGET) study, which showed that, in diabetic patients, the risk of stroke continues to decrease to a 
SBP value of 115 mm Hg with no evidence of J curve. As diabetes is highly associated with underlying coronary artery disease, 
there is a justified concern for adverse effects resulting from too much lowering of BP. In a post hoc analysis of 6400 diabetic sub-
jects enrolled in the International Verapamil SR-Trandolapril (INVEST) study, subjects with SBP of less than 110 mm Hg were as-
sociated with a significant increase in all-cause mortality. In the ONTARGET study, at any levels of achieved SBP, diastolic blood 
pressure (DBP) below 67 mm Hg was associated with increased risk for cardiovascular outcomes. As such, a prudent approach 
would be to target a SBP of 130–140 mm Hg and DBP of above 60 mm Hg in diabetics with coronary artery disease. In conclusion, 
hypertension, in association with diabetes, has been found to be significantly correlated with an elevated risk for cardiovascular 
events. As the association between stroke and BP is stronger in Asians, compared to other ethnicities, consideration should be 
given for a target BP of 130/80 mm Hg in Asians.
Key Words:  Diabetes, hypertension, blood pressure, stroke J-curve, coronary artery disease
Review Article
pISSN: 0513-5796 · eISSN: 1976-2437
Received: June 18, 2016
Corresponding author: Dr. Kazuomi Kario, Division of Cardiovascular Medicine, 
Department of Medicine, Jichi Medical University School of Medicine, 3311-1 
Yakushiji, Shimotsuke, Tochigi 329-0498, Japan.
Tel: 81-285-58-7538, Fax: 81-285-44-4311, E-mail: kkario@jichi.ac.jp
•The authors have no financial conflicts of interest.
© Copyright: Yonsei University College of Medicine 2016
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Yonsei Med J 2016 Nov;57(6):1307-1311
http://dx.doi.org/10.3349/ymj.2016.57.6.1307
1308
Target Blood Pressure in Diabetes
http://dx.doi.org/10.3349/ymj.2016.57.6.1307
betics, compared to non-diabetics, was increased by 1.89 to 4.40 
for varying systolic blood pressure (SBP) levels.4 In a subgroup 
analysis of the ONgoing Telmisartan Alone and in combination 
with Ramipril Global Endpoint Trial (ONTARGET) study, dia-
betic patients had a significantly higher risk for primary end-
point [hazard ratio (HR): 1.48, 95% confidence interval (CI): 
1.38–1.57], cardiovascular death (HR: 1.56, 95% CI: 1.42–1.71), 
myocardial infarction (HR: 1.30, 95% CI: 1.17–1.46), stroke (HR: 
1.39, 95% CI: 1.23–1.56), and congestive heart failure hospital-
ization (HR: 2.06, 95% CI: 1.82–2.32).5 As such, adequate treat-
ment of hypertension is essential to reduce the high burden of 
cardiovascular disease and end-stage renal disease in diabet-
ics. Until recently, a target blood pressure (BP) of 130/80 mm 
Hg was endorsed by major guidelines, such as the Joint Na-
tional Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC) VII, and the Europe-
an Society of Hypertension-European Society of Cardiology 
(ESH-ESC) guidelines.6,7 However, the results from the Action 
to Control Cardiovascular Risk in Diabetes (ACCORD) study 
have resulted in the revision of the target SBP to below 140 mm 
Hg according to ESH-ESC, JNC VIII, and the American Diabe-
tes Association (ADA) guidelines.8-10 In this minireview, we will 
discuss how recent changes in the guidelines may affect the 
target BP of diabetics in the Asian region. 
WHAT IS THE BASIS FOR THE REVISED 
TARGET BLOOD PRESSURE IN 
DIABETICS?
The clinical evidence for supporting a previous target BP of 
130/80 mm Hg was not based on results from an adequately 
powered, large-scale randomized study. Rather, the major sup-
porting evidence came from subgroup analysis of the hyperten-
sion optimal treatment (HOT) study. The objective of the HOT 
study was to assess the relationship between cardiovascular 
events and three different diastolic blood pressures (DBPs) of 
≤90 mm Hg, ≤85 mm Hg, and ≤80 mm Hg. Although the inten-
sive treatment failed to reduce the incidence of major cardio-
vascular events in the entire 18790 study subjects, there was a 
51% reduction in the incidence of major cardiovascular events 
among the 1501 patients who had diabetes at the onset of the 
study.11 Prior to the ACCORD, the only prospective study to 
achieve a mean BP below 130/80 mm Hg was the normoten-
sive Appropriate Blood Pressure Control in NIDDM (ABCD) 
trial study. This study randomized 480 diabetics with baseline 
BP below 140/90 mm Hg to intensive (10 mm Hg below the 
baseline DBP, mean BP: 128±0.8/75±0.3 mm Hg) versus mod-
erate (80–89 mm Hg of DBP, mean BP: 137±0.7/81±0.3 mm 
Hg) BP control. During a mean follow-up of 5.3 years, the in-
tensive treatment arm was associated with slowed progres-
sion of diabetic nephropathy, slowed progression of diabetic 
retinopathy, and lower incidence of stroke.12 However, the nor-
motensive ABCD study was a small study that did not have ad-
equate power to determine whether or not intensive BP re-
duction is more beneficial than conventional treatment in re-
ducing cardiovascular outcomes in diabetics. The lack of evi-
dence for the benefit of intensive BP lowering was the basis 
for the ACCORD BP trial. The ACCORD BP trial enrolled 4733 
participants with type 2 diabetes and randomized them to a 
target SBP of less than 120 mm Hg (after 1 year mean SBP: 119.3 
mm Hg) or 140 mm Hg (after 1 year mean SBP: 133.5 mm Hg). 
Despite the significant difference in the achieved SBP, there 
was no significant difference in the incidence of primary out-
come, defined as cardiovascular death, non fatal myocardial 
infarction, or non-fatal stroke (HR: 0.88, 95% CI: 0.73–1.06, 
p=0.20).13 The findings from the ACCORD study are supported 
by a post hoc analysis of the International Verapamil SR-Tran-
dolapril Study (INVEST study) in which 6400 diabetics patients 
(28%) enrolled in the INVEST study were analyzed according 
to the achieved mean SBP. Patients were categorized as tight 
control (mean SBP <130 mm Hg), usual control (130 mm Hg≤ 
mean SBP<140 mm Hg), and uncontrolled (mean SBP ≥140 
mm Hg). The results did not demonstrate any benefit of tight 
BP control compared to usual control in reducing primary out-
come, defined as all-cause mortality, non-fatal myocardial in-
farction, or non fatal stroke.14 Based on this evidence, the tar-
get SBP for diabetics has been revised by the majority of major 
hypertension guidelines.8-10 
SHOULD THE TARGET BLOOD PRESSURE 
FOR DIABETICS BE DIFFERENT IN THE 
ASIAN REGION?
In the Asian region, the association between BP and cardiovas-
cular disease differs, compared to other regions. In the Asia-
Pacific Cohort Studies Collaboration, a total of 425325 study 
participants were followed up for 3 million person-years. The 
study showed a steeper association between SBP and stroke in 
Asians, compared to an Australasian cohort (Fig. 1).15 After 
standardizing for age, a 10 mm Hg lower SBP was associated 
with 41% lower stroke in Asia and 30% lower stroke risk in 
Australasia.15 Also, stroke was the leading cause of cardiovascu-
lar mortality in Asians, whereas ischemic heart disease was the 
leading cause of mortality in Australasians (Fig. 1).15 This sug-
gests that target BP in the Asian region should be tailored to-
wards prevention of stroke. In the aforementioned ACCORD 
study, the intensive BP treatment was associated with signifi-
cant reduction in both total stroke (HR: 0.59, 95% CI: 0.39–
0.89, p=0.01) (Table 1) and non-fatal stroke (HR: 0.63, 95% CI: 
0.41–0.96, p=0.03) (Table 1). Although stroke was a secondary 
endpoint in the ACCORD study, the results may still have clin-
ical implications on the strong association of BP and stroke in 
the Asian region. The results from the ACCORD study are sup-
ported by a subgroup analysis from the ONTARGET study, 
1309
Sungha Park, et al.
http://dx.doi.org/10.3349/ymj.2016.57.6.1307
which showed that, in diabetic patients, the risk of stroke con-
tinued to decrease to an achieved SBP value of 115 mm Hg 
with no evidence of a J curve.5 Achieving SBP below 130 mm 
Hg, instead of 140 mm Hg, was associated with a 31.4% reduc-
tion in stroke, which is in line with the results from the AC-
CORD trial. In a meta-analysis of 13 randomized clinical trials 
Table 1. Primary and Secondary Outcomes of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus
Intensive therapy Standard therapy Hazard ratio  
(95% CI)
p value
No. of events %/yr No. of events %/yr
Primary outcome* 208 1.87 237 2.09 0.88 (0.73–1.06) 0.20
Prespecified secondary outcomes
Nonfatal myocardial infarction 126 1.13 146 1.28 0.87 (0.68–1.10) 0.25
Stroke
Any 36 0.32 62 0.53 0.59 (0.39–0.89) 0.01
Nonfatal 34 0.30 55 0.47 0.63 (0.41–0.96) 0.03
Death
From any cause 150 1.28 144 1.19 1.07 (0.82–1.35) 0.55
From cardiovascular cause 60 0.52 58 0.49 1.06 (0.74–1.52) 0.74
Primary outcome plus revascularization or 
  nonfatal heart failure
521 5.10 551 5.31 0.95 (0.84–1.07) 0.40
Major coronary disease event† 253 2.31 270 2.41 0.94 (0.79–1.12) 0.50
Fatal of nonfatal heart failure 83 0.73 90 0.78 0.94 (0.70–1.26) 0.67
CI, confidence interval.
Adapted from ACCORD Study Group, et al. N Engl J Med 2010;362:1575-85, with permission of Massachusetts Medical Society.13
*The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes, †Major coronary disease events, 
as defined in the protocol, included fatal coronary events, nonfatal myocardial infarction, and unstable angina.
Fig. 1. Asia Pacific Cohort Studies Collaboration: the study analyzed a total of 425325 study participants who were followed up for 3 million person-years. 
The study showed a steeper association between SBP and stroke in Asians, compared to an Australasian cohort. Stroke was the leading cause of car-
diovascular mortality in Asians, whereas ischemic heart disease was the leading cause of mortality in Australasians. Adapted from Lawes, et al. J Hyper-
tens 2003;21:707-16, with permission of Wolters Kluwer Health Inc.15 CI, confidence interval; SBP,  systolic blood pressure.
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involving 37376 participants with either diabetes mellitus or 
impaired fasting glucose, intensive SBP control (≤130 mm Hg) 
was associated with a greater reduction in stroke, but not in 
other major cardiovascular events.16 Also, in the normotensive 
ABCD study, intensive BP lowering (mean BP: 128±0.8/75±0.3 
mm Hg) was associated with a 69% reduction in stroke (p val-
ue=0.03).12 Although only a few randomized clinical outcome 
studies have been performed in the Asian region, some do sup-
port the application of a lower target SBP in diabetics. In the 
Challenge-DM study, a nationwide registry of 16869 Japanese 
patients followed up for 29 months, subjects with SBP ≥130 
mm Hg exhibited a 48% increased risk in primary events 
(p<0.001), compared to subjects with SBP <130 mm Hg.17 In a 
subgroup analysis from the CASE-J study, the risk of cardio-
vascular events was the lowest at SBP of <130 mm Hg and a 
DBP between 75–79 mm Hg.18 
Beyond prevention of stroke, intensive treatment of BP may 
be beneficial in subjects with diabetic nephropathy. In a post 
hoc analysis of the Renal Outcomes in the Irbesartan Diabetic 
Nephropathy Trial (IDNT), achieving SBP was a strong pre-
dictor of renal outcomes. Subjects with SBP >149 mm Hg were 
associated with a 2.2-fold increase in renal events, defined as 
doubling of serum creatinine or end stage renal disease (ESRD), 
compared to subjects with SBP <134 mm Hg.19 Progressive low-
ering of SBP to 120 mm Hg was associated with improved re-
nal outcomes and lower mortality, suggesting that a target 
SBP of 130 mm Hg is justified in subjects with diabetic ne-
phropathy.19 
The above evidence suggests that a target SBP of 130 mm 
Hg should still be considered for hypertensive subjects with 
diabetes in the Asian region, a recommendation that is still 
endorsed by the Taiwanese society of hypertension and the 
Japanese society of Hypertension.20,21 
HOW LOW CAN BLOOD PRESSURE BE 
LOWERED IN DIABETICS? 
Diabetes is strongly associated with underlying coronary ar-
tery disease.22 As such, there is a real and justified concern for 
adverse effects resulting from too much lowering of BP. In the 
post hoc analysis of 6400 diabetic subjects enrolled in the IN-
VEST study, subjects with a SBP of less than 110 mm Hg were 
associated with a significant increase in all-cause mortality 
(adjusted HR: 2.18, 95% CI: 1.17–4.09, p=0.02).14 This finding is 
supported by a post hoc analysis in the ONTARGET study. Ex-
cluding stroke, which did not show a J curve phenomenon, all 
other cardiovascular endpoints were associated with a nadir 
of SBP of 129.6 mm Hg in diabetics.5 Also, at any levels of 
achieved SBP, DBP of below 67 mm Hg was associated with in-
creased risk for cardiovascular outcomes.5 However, it should 
be cautioned that the post-hoc analyses were limited by the 
lack of randomization, and the number of patients with low or 
very low achieved BP was quite small.20 As J curve might be a 
real concern in diabetics with coronary artery disease, a pru-
dent approach would be to target a SBP of 130–140 mm Hg and 
a DBP above 60 mm Hg in diabetics with coronary artery dis-
ease. In diabetic subjects without any evidence of coronary 
artery disease, a SBP target of 130 mm Hg may be considered 
in the Asian region. In subjects with baseline SBP of less than 
140 mm Hg, treatment may be associated with increased car-
diovascular risk. In a meta-analysis of 73738 diabetic subjects 
by Brunström and Carlberg,23 treatment of BP in subjects with 
SBP of less than 140 mm Hg was associated with increased risk 
of cardiovascular mortality (HR: 1.15, 95% CI: 1.00–1.32) with 
a tendency towards an increased risk of all-cause mortality 
(HR: 1.05, 95% CI: 0.95–1.16). Therefore, anti-hypertensive 
treatment in diabetics should be started when BP is above 
140/90 mm Hg. Although the initial target should be to lower 
the BP to below 140/90 mm Hg, a target SBP of 130 mm Hg may 
be considered in Asians and patients with diabetic nephropa-
thy without prior history of coronary artery disease. However, 
it would be prudent to not lower the BP below 110/60 mm Hg. 
CONCLUSION
Hypertension in diabetics is associated with a significantly el-
evated risk for cardiovascular events. Anti-hypertensive treat-
ment should be started in all diabetics with a BP above 140/90 
mm Hg to lower the BP below 140/90 mm Hg. As the associa-
tion between stroke and BP is stronger in Asians than other 
ethnicities, consideration should be given for a target BP of 
130/80 mm Hg in Asians. However, it would be prudent to not 
lower the BP below 110/60 mm Hg, especially in subjects with 
a history of coronary artery disease. 
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